N4 Pharma Plc Regulatory News (N4P)

Onzima Ventures plc

("Onzima" or the "Company")

Final Results for year ended 31 December 2016

Onzima today announces its audited final results for the year ended 31 December 2016.

The audited Report and Accounts for the year ended 31 December 2016 will shortly be sent to shareholders and will also be available on the Company's website: www.onzimaventures.com.

For further information, please contact:

The Directors present their Strategic Report on the Company for the year ended 31 December 2016

REVIEW OF THE BUSINESS AND FUTURE DEVELOPMENTS

Following the disposal of the historical subsidiaries in October 2015, the Company commenced seeking to implement its investing policy. This continued during 2016 when the Company was extremely active, completing in excess of 100 transactions and investing in 19 companies as well as evaluating a number of potential reverse takeover opportunities.

On 1 March 2016, the Company announced that it had acquired 49% of N4 Pharma Limited ("N4 Pharma"), paying £41,000 in cash and issuing 24,272,807 new ordinary shares in Onzima. In addition, the Company agreed to provide a loan facility of £209,000 to N4 Pharma for the development of its business.

N4 Pharma is a private company that develops new versions of existing widely used drugs to provide an improved patient experience by reformulating its lead product is a novel patentable 'faster acting' version of Viagra which it will seek to out-license to a large pharma co-development partner. N4 Pharma has filed for 45 patents.

N4 Pharma was founded by Nigel Theobald, a successful healthcare entrepreneur with over 25 years' experience in the healthcare and biotech industry. Nigel previously worked in senior positions at Alliance Boots and is former CEO of Oxford Pharmascience Group Plc (AIM:OXP). He has a strong track record in developing intellectual property into commercial viable opportunities.

The funds were provided to accelerate the formulation work for N4 Pharma's novel sildenafil co-crystals (sildenafil is the generic drug name for Viagra) and undertake the initial proof of concept studies for their faster acting positioning. The erectile dysfunction market had global annual sales of approximately $4.6bn in 2016. Viagra came off patent in Europe in 2013 and is still the most widely used drug for erectile dysfunction despite it taking an hour before it starts to work. A faster acting version of Viagra will be a key new player in this attractive market. N4 Pharma also aims to expand its product portfolio and reformulate a wide range of drugs either already off patent or coming off patent soon, each of which having an equally attractive commercial opportunity. It was considered that N4 Pharma would provide regular news flow for Onzima and its investors.

As an Investing Company, the Company was required to implement its Investing Policy within 12 months of 14 October 2015 or make an acquisition or acquisitions which constitute a reverse takeover under the AIM Rules, failing which the Company's ordinary shares would be suspended from trading on AIM. As at close of business on 14 October 2016, the Company had not made an acquisition or acquisitions which constituted a reverse takeover under the AIM Rules or otherwise implemented its Investing Policy to the satisfaction of the London Stock Exchange. Accordingly, in accordance with Rule 15 of the AIM Rules for Companies, the Company's ordinary shares were suspended from trading with effect from 7:30 am on 17 October 2016.

On 17 January 2017, the Company announced that it had agreed in principle terms conditionally to acquire the 51 per cent. of the issued shares of N4 Pharma which it did not already own (the "Proposed Acquisition"). The consideration for the Proposed Acquisition would be satisfied by the issue of 36,409,210 new ordinary shares of 0.1p each in the capital of Onzima. It is intended that at the same time the Company would seek to raise approximately £3.0 million by way of a placing of new Ordinary Shares and an open offer to existing shareholders to fund development of additional patented reformulations of a wider range of generic drugs, to undertake clinical trials for the Company's reformulation of sildenafil and for working capital purposes.

The Proposed Acquisition will be classified as a reverse takeover under the AIM Rules and, as a result, is subject to the publication of an admission document in respect of the Company as enlarged by N4 Pharma setting out full details of the Proposed Acquisition and convening a general meeting of the Company where shareholders' approval will be sought for, among other things, the Proposed Acquisition and to change the Company's name to N4 Pharma plc.

Onzima is gradually monetising its share portfolio to provide funds for the continued development of N4 Pharma and the costs of the Proposed Acquisition. Following completion of the Proposed Acquisition, its trading division will cease to exist. In January 2017 Onzima also agreed to increase its loan facility to N4 Pharma from £209,000 to £309,000.

In anticipation of the Proposed Acquisition, the Company appointed Stockdale Securities Limited as its nominated adviser and broker.

It is expected that, subject to the completion of satisfactory due diligence, preparation of the requisite documentation and obtaining shareholders' approval, the Proposed Acquisition will be completed in mid-April 2017 ("Completion"). On Completion, it is expected that new directors will be appointed to the board of Onzima, including Nigel Theobald, the founder and Chief Executive of N4 Pharma, and that Professor Mughal and I will step down as directors of the Company.

CHIEF EXECUTIVE OFFICER'S STATEMENT

The year ended 31 December 2016 was another transformational year for the Company. In 2015 the historical subsidiaries were disposed of and the Company became an Investing Company.

Simultaneous with the disposals in October 2015 and a fundraising of £750,000 before expenses, Luke Cairns and I joined the Board as Directors to seek to implement the investing policy of the Company.

We sought to immediately be active but selective in our investments and prior to this financial year commencing we invested £50,000 in to Glenwick plc which we sold one month later at a 50% profit.

During 2016 and prior to the suspension of trading on AIM in the Company's shares on 17 October 2016 we continued to build the investment portfolio in line with our investing policy, most notably with the acquisition of 49% of N4 Pharma, a very exciting pharmaceutical drug reformulation company.

We established an asset trading division and a business development division in order to separate our various positions. The asset trading division would focus on publicly traded investments and the business development division would focus on private opportunities such as N4 Pharma.

We made numerous exciting investments in to companies within the natural resources sector obtaining equity and in some cases warrant positions including Alecto Minerals plc, Ariana Resources plc, Bezant Resources plc, Bushveld Minerals Limited, ECR Minerals plc, Ferrum Crescent Limited, Hummingbird Resources plc, Hurricane Energy plc, Jubilee Platinum plc, MX Oil plc, Nu-Oil & Gas plc, Prospex Oil & Gas plc, Regency Mines plc and Savannah Resourcesplc.

On 17 January 2017, we announced the proposed conditional acquisition of the 51% equity of N4 Pharma that we did not already own and the appointment of advisers to assist us with the completion of the transaction which would constitute a reverse takeover, a fundraise of approximately £3 million and re-admission to AIM.

In almost all cases we have now disposed of our listed investments and retain a number of warrant positions that we shall seek to monetise in due course where possible.

We have been pleased with the performance of the Company during the year and are very excited about the future prospects for N4 Pharma which could generate very substantial returns for Onzima shareholders.

FINANCIAL

During 2016, the Company made a loss from continuing operations of £22,000 (2015: loss of £151,000). The Company's assets at 31 December 2016 include investments of £302,000 (2015: £50,000) and cash balances amounting to £172,000 (2015: £587,000).

REVIEW OF THE YEAR

During 2016 Onzima made investments pursuant to its investing policy utilising the net proceeds of funds raised in October 2015 when the Company became an investing company under the AIM Rules.

The Company was extremely active and completed over 100 transactions prior to October 2016.

Unfortunately, as the Company had not fulfilled its investing policy under the AIM Rules, trading in the Company's shares was suspended from 17 October 2016.

The Board was otherwise pleased with the Company's progress, including the variety of investments made and the returns made on its investments, together with the portfolio that it was successfully creating.

The Board entered negotiations with Nigel Theobald, founder of N4 Pharma, to acquire the remaining 51% of N4 Pharma. These negotiations were successful and the Board is excited about the future potential of the group assuming completion of the reverse takeover transaction.

OUTLOOK AND STRATEGY

Since the re-financing and disposal of the subsidiaries the Company made good progress with establishing its portfolio of investments. The Company also sought to maintain a reasonable cash balance for the purpose of making new investments.

Since Onzima was restructured in October 2015, the main focus has been on investing in opportunities within the natural resources sector that (provided scope to make significant gains in financing their development.)

Though the sector remained difficult during early 2016, the strategy has to date been successful and has yielded reasonable returns.

In order to diversify the portfolio, we took a significant stake in N4 Pharma, an early stage but very exciting company within the pharmaceutical space. The market reacted well to this position and we have now agreed to conditionally buy the other 51% of N4 Pharma to take our holding to 100% ownership.

We believe that N4 Pharma represents a very exciting opportunity in a multi-billion-dollar marketplace.

Key Developments and Outlook

In line with the Investing Policy, the Board have been very active and sought suitable investments.

On 1 March 2016 Onzima acquired a 49% stake in N4 Pharma for £41,000 cash together with the issue of 24,272,807 new ordinary shares in Onzima alongside the provision of a loan facility to N4 Pharma of £209,000. N4 Pharma is a private company that develops new versions of existing widely used drugs to provide an improved patient experience by reformulating them. They continue to make positive progress through potential partners.

On 17 January 2017, the Company announced that it had agreed in principle terms conditionally to acquire the 51 per cent. of the issued shares of N4 Pharma which it did not already own. The consideration for the Proposed Acquisition will be satisfied by the issue of 36,409,210 new ordinary shares of 0.1p each in the capital of Onzima. It is intended that at the same time the Company will seek to raise approximately £3.0 million by way of a placing of new Ordinary Shares plus an open offer of up to £1.0 million to fund development of additional patented reformulations of a wider range of generic drugs, to undertake clinical trials for the Company's reformulation of Sildenafil and for working capital purposes.

The Proposed Acquisition will be classified as a reverse takeover under the AIM Rules and, as a result, is subject to the publication of an admission document in respect of the Company as enlarged by N4 Pharma setting out full details of the Proposed Acquisition and convening a general meeting of the Company where shareholders' approval will be sought for, among other things, the Proposed Acquisition and to change the Company's name to N4 Pharma plc.

It is the Board's intention to now complete the Proposed Acquisition.

Principal risks and uncertainties

Operational

The Company presently invests a significant proportion of its available capital in to natural resource companies and early stage companies generally. Some of these companies may also be unlisted or illiquid to trade. There is a risk that some of these investments may not produce a positive return for the Company and some of them may fail entirely.

At this stage in its development the Company may be reliant upon raising further funds from investors to support its growth. There is no guarantee that these funds will be available to the Company. In addition, there is no guarantee that the acquisition of N4 Pharma Limited will complete.

The principal risks and uncertainties facing the Company relate to the Proposed Acquisition. There is a risk that this transaction does not complete. In this event the Company's shares will be delisted from AIM and the Company may not be able to fund its future operations.

The Group's financial instruments comprise cash and various items, such as trade receivables and accruals that arise directly from its operations. The Group's exposure to its financial instruments is not material and therefore derivative financial instruments are not used to hedge this exposure.

The main risk arising from the Group's financial instruments can be analysed as follows:

Liquidity risk

The Group has sufficient cash resources available to meet its short term liabilities.

The Company's shares are currently suspended from trading on AIM and there is no guarantee that they will be readmitted to trading.

Interest rate risk

The Group has no borrowings and receives variable interest based on UK bank base rates on cash balances and bank deposits.

Payment to creditors

The Group does not follow any code or standard on payment practice and the terms and conditions for its business transactions are agreed with individual suppliers. Payment is then made in accordance with those terms, subject to the other terms and conditions being met by the supplier. Creditor days at the end of the year for the group were nil days (2015: nil days).

Key Performance Indicators & Financial Performance

The Board intends to review key performance indicators as the business progresses, at this stage of the Company's life cycle, it is not yet able to measure key performance indicators in any meaningful way. The Board intends to publish key performance indicators in future years.

At the year end the Company had cash at bank of £172,000 (2015: £587,000). The cash is the primary asset of the Company and enables it to select suitable investments. As identified as a risk, in time, further funding may be required which with careful and selective investment criteria should be possible to secure.

Going Concern

Accounting standards require the directors to consider the appropriateness of the going concern basis when preparing the financial statements. The Directors confirm that they consider that the going concern basis remains appropriate. The Directors regard the going concern basis as remaining appropriate as the Company and Group have adequate resources to continue in operational existence for the foreseeable future, coupled with experienced Directors that are able to seek out additional funding if they believe that it is necessary.

In closing, the Board would like to extend their thanks to all their shareholders for their continued support and look forward to a successful next year.

The directors present their annual report and audited financial statements of Onzima Ventures plc for the year ended 31 December 2016.

Business review and principal activities

The principal activities of the Group during the year were in line with the adoption of the Investing Policy as set out below.

Investing Policy

The Company will seek to invest a minimum of 75 per cent. of its deployable capital in, and/or acquire companies or interests within, the natural resources sector - in which the new Directors have substantial experience as founders, investors and advisers.

The Company was participating as an investor in fundraisings for entities being admitted to trading on AIM, in secondary fundraisings, or where such entities plan to be admitted to trading on an Exchange within 18 months of investment by the Company.

The Company does not plan to have cross-holdings in entities save where there is a portfolio of related assets outside of the Company's control.

The Board considers that as investments are made, and new investment opportunities arise, further funding of the Company may also be required which is likely to be in the form of equity, until such time as the Company is self-funding.

It is intended that returns for Shareholders will initially be in the form of capital growth, subject to appreciation in the value of the investments made by the Company. In the longer term, if the Company becomes cash generative, then the plan will be to put in place an appropriate dividend policy as appropriate for a Company with its activities at that time.

The Company plans to have a maximum of fifteen investments / interests at any one time. Though there will be no maximum exposure to any one investment, it will generally seek to diversify its portfolio holdings. The Company's financial resources may ultimately be invested in a number of propositions or in just one investment, which may be deemed to be a reverse takeover pursuant to Rule 14 of the AIM Rules requiring shareholder approval.

The Company also intends to acquire over a period of time a diversified portfolio of royalties. These will consist, in varying proportions, of royalties over:

- producing properties purchased at a discount to perceived value;

- producing properties with enhanced production possibilities; and

- non-producing properties where advanced exploration is likely.

It is intended that over the longer term the royalty investments will provide cash flow to finance further investment opportunities, minimising dilution to Shareholders through reduced equity financing requirements. The Company does not currently intend to fund any investments with debt or other borrowings but may do so if appropriate. The Board may also offer New Ordinary Shares in the capital of the Company by way of consideration as well as utilising cash, preserving the Company's cash for additional opportunities and working capital.

Under the Company's investing policy, the remaining 25 per cent. of the Company's deployable capital can be invested in to non-natural resource based interests that fit the same criteria as above.

Directors

The Directors during the year under review were:

Gavin Burnell

Luke Cairns

Humayun Mughal

Biographies for each current director can be found on the Company's website: www.onzimaventures.com.

Results and dividends

The Group loss for the year before taxation amounted to £22,000 (2015: loss of £164,000), taxation refund for the year of £Nil (2015: £13,000) and a loss after tax of £22,000 (2015: loss of £151,000). Total comprehensive income for the year was £(22,000) (2015: £(1,000,000).

The directors do not recommend the payment of a dividend for 2016. No dividends were paid or proposed in 2015.

Employees

The Company does not currently employ any staff. The Directors act for the Company in implementing its Investing Policy.

Substantial Interests

At 16 March 2017 the following parties had notified the Company of a beneficial interest that represents 3% or more of the Company's issued ordinary share capital at that date:

Directors and Directors' interest

The Directors who are currently in office are shown on page 9. The emoluments, share interest and share options of the Directors are disclosed in the Directors Remuneration Report on pages 15 to 16.

Employees

It is Group policy that employees should be kept as fully informed as is feasible and practicable about the activities of the Group through consultative meetings. In addition, managers hold regular meetings with representatives of their staff in order to encourage employees to make their views known on matters that affect them.

Pensions

No contributions were paid in respect of the Directors.

Events after reporting date

On 17 January 2017, the Company announced that it had agreed in principle terms conditionally to acquire the 51% on the issued shares of N4 Pharma Limited which it does not already own. The consideration for the acquisition will be satisfied by the issue of 36,409,210 new ordinary shares.

Share Option schemes

The Company's Microvitec 1994 Inland Revenue Approved Executive Share Option Scheme approved by the Company in the Annual General Meeting 1994 has now terminated (the "Old Scheme"). There are no options to acquire ordinary shares in the capital of the Company outstanding under the Old Scheme (2013: Nil).

Ultima Networks Plc 2004 Share Option Scheme

The scheme was approved by the AGM held on 28 May 2004. No options to subscribe for ordinary shares of 1p each have been granted to date.

Ultima Networks Plc 2012 Share Option Scheme

The scheme was approved by the AGM held on 26th June 2012. No options to subscribe for ordinary shares of 1p each have been granted to date.

Options were issued to G Burnell and L Cairns. (For further details refer to note 26)

Charitable and political contributions

There were no donations to UK charitable organisations (2015: £Nil) and no political donations (2015: £Nil).

Directors' responsibilities

The directors are responsible for preparing the strategic report, directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have, as required by the AIM Rules, elected to prepare the group and company financial statements in accordance with International Financial Reporting Standards as adopted by the European Union. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements the directors are required to:

• select suitable accounting policies and then apply them consistently;

• make judgments and estimates that are reasonable and prudent;

• state whether the group financial statements have been prepared in accordance with IFRS's as adopted by the European Union;

• state, with regard to the parent company financial statements, whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

• prepare the financial statements on a going concern basis unless it is inappropriate to presume that company and the group will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions that disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of any corporate and financial information included on the company's website. Legislation in the UK governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Statement of disclosure to auditors

So far as each Director is aware, there is no relevant audit information of which the Company and Group auditors are unaware. Additionally, the Directors have taken all the steps that they ought to have taken as Directors in order to make themselves aware of any relevant audit information and to establish that the Company and Group auditors are aware of the information.

Annual General Meeting

The Annual General Meeting of the Company is to be held at 2 Stone Buildings, Lincolns Inn, London WC2A 3TH on Tuesday 18 April 2017 at 10.15am.

Approval

The Report of the Directors was approved by the Board on 22 March 2017.

As a company which shares are admitted to trading on the AIM Market of the London Stock Exchange, the Company is not required to comply with the provisions of the 2006 Financial Reporting Council's revised combined Code. However, the Board has sought to commit to ensuring that proper standards of corporate governance operate throughout the Group and has therefore followed the principles of the Code so far as is practicable and appropriate to the nature and size of the Group. One of the principles is that an explanation should be given where the Code is not complied with. A statement of the directors' responsibilities in respect of the financial statements is contained within the Report of the Directors above. The statement below describes the role of the Board and its committees, followed by a statement regarding the groups system of internal controls.

The Board

The activities of the Group are ultimately controlled by the Board of Directors, which at the year-end consisted of three directors. Biographical details of all three directors are available on the Company's website. All directors are equally accountable under law for the proper stewardship of the Company's affairs. The Non-executive director has a particular responsibility to ensure that the strategies proposed by the Executive director are fully discussed and critically examined.

The Non-executive directors are Luke Cairns and Humayun Mughal and the Board considers Luke Cairns to be independent.

The Board meets at least four times a year, and more as the need arises. The Board reviews performance of investments, its strategy, examines capital expenditure and acquisitions or disposals, operating budgets and material contracts.

All directors have letters of appointment with the Company. Any director appointed during the year is required, under the Company's Articles of Association, to retire and seek re-election by the shareholders at the next Annual General Meeting and one third of the Board is required to retire each year and seek re-election. The directors are able to take independent professional advice at the expense of the company in the furtherance of their duties.

Nominations committee

The appointment of directors is a matter for the Board as a whole and therefore a nominations committee is considered unnecessary given the present number of Board members.

Audit committee

The Audit committee comprises of the two non-executive directors: Luke Cairns and Humayun Mughal. This committee assists the Board in its duties regarding the Group's financial statements and the maintenance of adequate internal financial controls. The Audit Committee's prime tasks are to receive reports from the Company's auditors, Jeffreys Henry LLP, and to review the half-yearly and annual accounts before they are presented to the Board, focusing in particular on accounting policies and compliance and areas of management judgements and estimates.

There is no internal audit function for the Group, as the Board does not believe that this is appropriate given the size of the business.

Remuneration committee

The Remuneration Committee comprises of the two Non-executive directors Luke Cairns and Humayun Mughal. Details of the executive remuneration policy are set out in the separate Directors' Remuneration Report on pages 15 and 16.

Shareholder relations

The Board has a policy of providing any reasonably requested historical information and explanations to shareholders on request. The Group's annual reports are sent to shareholders. These reports are also available from the company's website along with the Group's half yearly reports and all public announcements. All shareholders are encouraged to participate in the company's Annual General Meeting, which is attended by the directors.

Internal control and financial reporting

The Board is responsible for ensuring that there is a system of internal control for reviewing its effectiveness. Such a system is designed to manage rather than eliminate the risk of failure to achieve business objectives and can only provide reasonable and not absolute assurance against material misstatement or loss. The Audit Committee has been delegated responsibility by the Board for discharging its internal control responsibilities.

The Board has established an organisational structure with clearly defined levels of responsibility and delegation of authority. Control procedures include annual budget approval and monitoring of actual performance. The Board approves all investment and acquisition projects for all major acquisitions and major capital expenditure.

The Board has a clear responsibility for identifying risks facing each of the businesses and for putting in place procedures to mitigate and monitor risks. As part of the annual budgeting process risks are formally assessed by the Board.

There is a system of financial reporting and budget planning. On a monthly basis, actual results are reported and compared to budget with any significant adverse variances being examined and any remedial action taken as necessary.

The directors believe that, taken as a whole, the systems of internal control are appropriate to the business for the year ended 31 December 2016.

The directors present the Directors remuneration report for the year ended 31 December 2016. It should be noted that, as a company quoted on the AIM market of the London Stock Exchange, the company is not required to comply with the Remuneration Report regulations and therefore, not all elements of the regulations have been complied with. For example, a share price graph has been omitted.

Remuneration committee

The Remuneration committee consists of Non-executive directors Luke Cairns and Humayun Mughal.

The Remuneration committee determines any remuneration and benefits packages of the executive directors and considers any service contracts, salaries, other benefits, including bonuses and participation in the company's share option plans, and any other terms and conditions of employment including any compensation payments on termination of office.

Remuneration policy

Any basic salaries and benefits in kind are set to be comparable with those of peer group companies. The Company operates historic share schemes but these do not form part of the current remuneration policy. It is planned to put in place a formal share option scheme in due course.

Non-executive directors

The Non-executive directors do not have a contract for services. The Non-executive directors have letters of appointment concerning, amongst other things, the initial terms for which he was appointed, a general statement of their role and duties, the fees they will receive as a director and any supplementary fees receivable for additional work, such as being a member of more than one Board committee. The fees of Non-executive directors are determined by the full Board within the limits set out in the Memorandum and Articles of Association.

Service contracts and letters of appointment

The company does not have service contracts in respect of the Executive Directors. The letters of appointment in respect of the Non-executive directors who served during the year ended 31 December 2016 is for a rolling 12-month period. The letters of appointment contain notice periods for non-executive directors of 1 month executive directors of 6 months and no provision for termination payments.

Directors' remuneration and interests

Directors' remuneration payable for the year ended 31 December 2016 was as follows:

The beneficial interest in the share capital of the Company of those persons, who were directors at the year end, as recorded in the register of the Directors' interest, were as follows:

Gavin Burnell and Luke Cairns directors of the Company were granted share options over 10,804,840 and 2,701,210 shares respectively on 14 October 2015. No director has granted or exercised any share options during this or the previous year nor did any lapse.

Directors' remuneration and interests

Beneficial holdings include the directors' personal holdings and those of their spouse and children as well as holdings in family trusts of which the directors' spouse or their children are beneficiaries or potential beneficiaries.

The closing mid-market price at 16 October 2016 when the ordinary shares were suspended from trading was 1.25p and the range during the year was 1.95p to 0.425p.

Approval

The Directors' Remuneration Report was approved by the Board on 22 March 2017.

We have audited the financial statements of Onzima Ventures Plc for the year ended 31 December 2016, which comprise the Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Statement of Financial Position, Company Statement of Financial Position, Consolidated Statement of Cash Flows, Company Statement of Cash Flows and the related notes on pages 19 to 52. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards (IFRSs) as adopted by the European Union and as regards the parent company financial statements as applied in accordance with the provisions of the Companies Act 2006.

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As explained more fully in the Statement of Directors' Responsibilities set out on page 11, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the Group's and Parent Company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Financial Highlights and Strategic Report and Directors' Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatement or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion:

• the financial statements give a true and fair view of the state of the group's and of the parent company's state of affairs as at 31 December 2016 and of the group's loss and the group's and parent company's cash flow for the year then ended;

• the group financial statements have been properly prepared in accordance with IFRS's as adopted by the European Union;

• the parent company financial statements have been properly prepared in accordance with IFRS's as adopted by the European Union and as applied in accordance with the provisions of the Companies Act 2006; and

• the financial statements have been prepared in accordance with the provisions of the Companies Act 2006.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion the information given in the Strategic Report and Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or

- the parent company financial statements are not in agreement with the accounting records and returns; or

- certain disclosures of directors' remuneration specified by law are not made; or

- we have not received all the information and explanations we require for our audit.

Sachin Ramaiya (Senior Statutory Auditor)

For and on behalf of Jeffreys Henry LLP, statutory auditor

Finsgate

5-7 Cranwood Street

London

EC1V 9EE

United Kingdom

Date: 22 March 2017

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

AS AT 31 DECEMBER 2016

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2016

These financial statements were approved and authorised for issue by the board of directors on 22 March 2017 and were signed on its behalf by:

........................................................................

Gavin Burnell

Chief Executive Officer

Company Registration Number 01435584

COMPANY STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2016

These financial statements were approved and authorised for issue by the board of directors on 22 March 2017 and were signed on its behalf by:

........................................................................

Gavin Burnell

Chief Executive Officer

Company Registration Number 01435584

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2016

1. GENERAL INFORMATION

In the prior year Onzima Ventures Plc ("the Company") and its subsidiaries (together "the Group") were involved in the marketing and support of computer application software and the merchandising of various products, but primarily electric bicycles. The company sold the subsidiaries on 14 October 2015 and operates now as an investment holding company.

The company is a public limited company, which is quoted on the AIM of The London Stock Exchange and is incorporated and domiciled in the United Kingdom. The address of its registered office is 6th Floor, Gracechurch Street, London, EC3V 0HR.

The Group's and company's financial statements for the year ended 31 December 2016, were authorised for issue by the Board of Directors on 22 March 2017 and the balance sheets were signed on the Boards behalf by Gavin Burnell.

2. ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been applied consistently to all years presented, unless otherwise stated.

Basis of preparation

These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and the interpretations of the International Financial Reporting Interpretations Committee (IFRIC) as adopted by the European Union, and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS.

These financial statements have been prepared on the historic cost basis except where financial instruments are required to be carried at fair value under IFRS.

The financial statements are presented in pounds sterling, being the functional currency of the parent and all values are rounded to the nearest thousand pounds (£000) except where otherwise indicated.

Going concern

Having reviewed the future plans and projections for the business, the directors are satisfied that the Company and Group have adequate resources to continue to operate for the foreseeable future, a period not less than twelve months from the date of approval of the financial statements. This will also depend on the continuing support from the shareholders and directors. For these reasons, the directors continue to adopt the going concern basis in preparing the financial statements.

Were the group and company unable to continue as a going concern, adjustments would have to be made to the statement of financial position of the group and company to reduce the value of assets to their recoverable amounts, to provide for future liabilities that might arise and to reclassify non-current assets and long-term liabilities as current assets and liabilities.

Basis of consolidation

The consolidated financial statements incorporate the results and net assets of Onzima Ventures Plc and its subsidiary undertakings (together referred to as "the Group") for the year ended 31 December 2016. A subsidiary is an entity over which the Group has the power to govern the financial and operating policies generally accompanying a shareholding of more than 50% of the voting rights. The results of each subsidiary are included from the date that control transferred to the group and are adjusted to align accounting policies with the Group's accounting policies. Subsidiaries are no longer consolidated from the date that control ceases. Unrealised gains on transactions between the group and its subsidiaries are eliminated and unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. All intercompany balances and transactions are eliminated in full. Amounts reported in the financial statements of subsidiaries have been adjusted where necessary to ensure consistency with the accounting policies adopted by the group.

Company investment in subsidiaries

In its separate financial statements, the company recognises its investments in subsidiaries at cost. Income is recognised from these investments only in relation to distributions received from post acquisition profits.

Share-based payments

For equity settled share based payment transactions the Group, in accordance with IFRS 2 "Share Based Payments" measures their value, and the corresponding increase in equity, indirectly, by reference to the fair value of the equity instruments granted. The fair value of those equity instruments is measured at the grant date using the Black-Scholes method. The expense is apportioned over the vesting period of the financial instrument and is based on the number which is expected to vest and the fair value of those financial instruments at the date of grant. If the equity instruments granted vested immediately, the expense is recognised in full.

Other intangible assets

Other intangible assets include technology platform and customer relationships. These are only recognised if acquired in a business combination. They are stated at fair value less accumulated amortisation. These assets are amortised over their estimated useful lives of 10 years and the charge is included in administration expenses.

Revenue recognition

Revenue is recognised at the point of sale of the investments.

Segment reporting

A business segment is a group of assets and operations engaged in providing products or services that are subject to risks and returns that are different from those of other business segments and whose operating results are reviewed on a regular basis by the Group's board and for which discrete financial information is available. A geographical segment is engaged in providing products or services within a particular economic environment that is subject to risks and returns that are different form those of segments operating in other economic environments.

Property, plant and equipment

Property, plant and equipment is carried at cost less accumulated depreciation and any recognised impairment in value. Cost comprises the aggregate amount paid to acquire the asset and includes costs directly attributable to making the asset capable of operating as intended.

All land and buildings are included at valuation. Valuations are kept up-to-date through periodic valuations carried out by external valuers.

Depreciation is provided evenly on the cost (or valuation where appropriate) of the assets, to write them down to their estimated residual values over their expected useful lives. No depreciation is provided on freehold land. The principal annual rates used for the other assets are:

Freehold buildings - 25 to 50 years

Office equipment - 3 to 5 years

Motor vans - 4 years

Computer equipment - 3 years

The assets' residual values, useful lives and methods of depreciation are reviewed, and adjusted, if appropriate, on an annual basis. An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. A gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement in the year that the asset is derecognised.

Impairment of assets

At each balance sheet date, the Group reviews the carrying amounts of its property, plant and equipment and intangible assets to determine whether there is any indication that these assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset, which is the higher of its fair value less costs to sell and its value in use, is estimated in order to determine the extent of the impairment loss. Where the asset does not generate cash flows that are independent from other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

An impairment charge is recognised in the income statement in the year in which it occurs. With the exception of goodwill, all assets are subsequently reassessed for indications that an impairment loss previously recognised may no longer exist. The carrying amount of the asset is increased to the revised estimate of its recoverable amount. The increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years.

Inventories

Inventories are investments and valued at the lower of cost and net realisable value. In the prior year to 14 October 2015 cost of raw materials, consumables and goods purchased for resale means actual price, including transport and handling and is determined using FIFO method. Net realisable value means estimated net selling price less estimated costs of disposal.

Trade and other receivables

Trade receivables are recognised initially stated at fair value and subsequently measured at amortised cost using the effective interest rate method. Provision against trade receivables is made when there is objective evidence that the Group will not be able to collect all amounts due to it in accordance with the original terms of those receivables. The amount of the write-down is determined as the difference between the asset's carrying amount and the present value of estimatedfuturecashflows.

Cash and cash equivalents

Cash and cash equivalents includes cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within financial liabilities in current liabilities on the balance sheet.

Trade and other payables

Trade payables are not interest bearing and are initially stated at their fair value and then subsequently measured at amortised cost using the effective interest method.

Income taxes

Current income tax assets and liabilities are measured at the amount expected to be recovered or paid to the taxation authorities, based on tax rates and laws that are enacted or substantively enacted by the balance sheet date.

Deferred income tax is recognised using balance sheet liability method, providing for temporary differences between the tax bases and the accounting bases of assets and liabilities. Deferred income tax is calculated on an undiscounted basis at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised, based on tax rates and law enacted or substantively enacted at the balance sheet date.

Deferred income tax liabilities are recognised for all temporary differences, except when deferred income tax liabilities arise from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and at the time of transaction, affects neither the accounting profit nor taxable profit or loss.

Deferred income tax is charged or credited to the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred income tax assets and liabilities are offset against each other only when the Group has a legal enforceable right to do so.

Deferred income tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the deductible temporary differences can be utilised.

Pensions

The Group does not operate any pension schemes, but does contribute to the personal pension schemes (defined contribution) of certain staff. The contributions are charged as an expense as they fall due. Any contributions unpaid at the balance sheet date are included as an accrual at that date. The Group has no future payment obligations once the contributions have been paid.

Leased assets - Group as lessee

Leases are classified as finance leases when the terms of the lease transfer substantially all the risks and rewards of ownership to the Group. All other leases are classified as operating leases.

Assets leased under operating leases are not recorded on the balance sheet. Rentals payable are charged direct to the income statement. Lease incentives, for example, up-front cash payments or rent free periods, are capitalised and spread over the period of the leased term. Payments made to acquire operating leases are treated as prepaid lease expenses and amortised over the useful life of the lease.

Leased asset - Group as lessor

Assets leased out under operating leases are included in property, plant and equipment and depreciated over their useful lives. Rental income, including the effect of lease incentives, is recognised on a straight line basis over the lease term.

Components of equity

Equity comprises the following:

· Share capital represents the nominal value of equity shares,

· Share premium represents the excess over nominal value of the fair value of consideration received for equity shares, net of expenses of the share issue,

· Other reserves represents Merger Reserve and represents the difference between the value of the shares acquired and the nominal value where the shares have been issued as part of the consideration for acquisitions, and

· Share options reserves relate to the charge for the share based payment in accordance with IFRS 2.

· Profit and loss reserve represents retained profits.

Use of assumptions and estimates

The Group makes judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The resulting accounting estimates calculated using these judgements and assumptions will, by definition, seldom equal the related actual results but are based on historical experience and expectations of future events. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of revisions and future periods if the revision affects both current and future periods.

The estimates and assumptions that have a significant effect on the amounts recognised in the financial statements are:

· Estimates in relation to future cash flows and discount rates utilised in impairment testing,

· Management intentions for realisation of tax assets and liabilities under IAS 12.

· Cash flow forecasts relating to the impairment review of the investment in N4 Pharma.

STATEMENT OF COMPLIANCE

Issued International Financial Reporting Standards (IFRS) and Interpretations Committee (IFRIC) relevant to the Group Operations

There are no IFRS or IFRIC interpretations that are effective for the first time in this financial period that would be expected to have a material impact on the Company.

Standards, interpretations and amendments to published standards that are not yet effective

There are no other IFRS and IFRIC interpretations that are not yet effective that would be expected to have a material impacts on the company.

3. SEGMENTAL REPORTING

The Group operated in the United Kingdom, Italy and Spain until its subsidiaries sold on 14 October 2015.

Prior to disposal, the Group was organised into two principal business segments:

· IT and related services (comprising legal and publishing application software)

· Green technology (comprising electric bicycles, energy saving lamps, educational electronic kits and development of solar power parks)

The company now operates as an investment holding company.

The segmental results for the year ended 31 December 2016 are as follows:

The segmental results for the year ended 31 December 2015 were as follows:

The other information of the segments was as follows:

4. PRESENTATIONAL ADJSTMENTS

The prior year results have been presented to reflect the discontinued operation in 2015. Refer to note 6 for more details.

5. OPERATING PROFIT

6. DISCONTINUED OPERATIONS

On the 25 September 2015, the group entered into a sale agreement to dispose of Cognito Software Solutions Limited, UTN Solutions (North) Limited and Tre-Sol Italia srl, which carried out all of the group's operations. The disposal was completed on 14 October 2015 on which date control passed to the acquirer.

The results of the discontinued operations, which have been included in the consolidated income statement, were as follows:

7. AUDITORS REMUNERATION

 Services provided by the Company's auditor and its associates

8. FINANCE INCOME & EXPENSE

9. EMPLOYEES